Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 12;193(15):E521.
doi: 10.1503/cmaj.210066. Epub 2021 Mar 9.

Tocilizumab for hospitalized patients with COVID-19

Kevin Afra  1 , Luke Y C Chen  2 , David Sweet  2
Affiliations

Tocilizumab for hospitalized patients with COVID-19

Kevin Afra et al. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Kevin Afra and Luke Chen are members, and David Sweet is chair, of the B.C. COVID-19 Therapeutics Committee, which provides guidance on the most current research on use of therapies in management of COVID-19. Luke Chen has received support from GlaxoSmithKline for an ad board for mepolizumab. No other competing interests were declared.

References

    1. Chen LYC, Hoiland RL, Stukas S, et al. . Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Eur Respir J 2020;56:2003006. - PMC - PubMed
    1. Product monograph: PrActemra (tocilizumab). Mississauga (ON): Hoffmann-La Roche; 2010. April. 30, revised 2021 Jan. 4. Available: https://pdf.hres.ca/dpd_pm/00059560.PDF (2021 Feb. 12).
    1. REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, et al. . Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med 2021. Feb. 25 [Epub ahead of print]. 10.1056/NEJMoa2100433. - DOI - PMC - PubMed
    1. RECOVERY Collaborative Group; Horby PW, Pessoa-Amorim G, Peto L, et al. . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial [preprint]. medRxiv 2021. Feb. 11. 10.1101/2021.02.11.21249258. - DOI

MeSH terms